Organization (WHO), approximately 18.5 million people have a history of HCV infection, and nearly 350 000 people die of HCV-related diseases annually.
| Source of samples
Serum
| ME THODS

| Preparation of solid-phase antigens
Recombinant HCV antigens were diluted with a coating buffer containing 50 mmol/L Na 2 CO 3 -NaHCO 3 (pH 9.6), and 100 μL coating buffer was added to each well of a 96-well microtiter plate and incubated overnight at 4°C. The coating buffer was discarded, and each well was blocked with 100 μL of 3 g/L BSA at room temperature for 2 hours. The blocking buffer was discarded, and the plates were dried under a vacuum and stored at −20°C in a sealed plastic bag with a desiccant until use. 
| Preparation of labeled antibodies
| Establishment of the HCV-IgM/IgG TRFIA
The assay is summarized in Figure 1 . In brief, after diluting the serum with buffer 200 times, 100 μL of test serum or positive or negative control serum was added to microplates coated with HCV antigens.
After incubation at 25°C with shaking for 45 minutes, the plates were washed five times with washing solution before the addition of 100 μL/ 
| Methodological assessment and statistical analysis
The sensitivity, specificity, precision, and stability of the assay were compared with those obtained using existing methods. SPSS 13.0 was used for statistical analyses. 
| RE SULTS
| Labeling rate
| Optimal antibody labeling concentration
The labeled antibodies from the reaction step were diluted 1:10, Thus, we obtained the optimal dilutions for Eu 3+ -rabbit anti-human IgM (1:100) and Sm 3+ -rabbit anti-human IgG (1:50).
| Optimal serum dilution
The negative serum was diluted 1:25, 1:50, 1:100, 1:200, 1:400, and 1:800 with the buffer to decrease nonspecific adsorption. The decline in the fluorescence value tended to plateau as the sample dilution increased, and 1:200 was the optimal serum dilution ( Figure 2 ).
| Confirmation of positive cutoff values (CO values)
The Eu 
| Precision
Samples with high, medium, and low concentrations were tested 10 times under similar experimental conditions within 8 days ( Table 2 ).
The mean intra-assay Circulation Volume (CV) for IgM and IgG were 3.45% and 3.71%, respectively, and the mean inter-assay CV were 6.49% and 6.79%, respectively. The mean intra-assay CV was less than 10% and the mean inter-assay CV was less than 15%, showing that our method has good precision.
| Comparative tests
The 
| Clinical applications
The (Table 4 ). benefits, such as a high sensitivity, wide linear range, and good tracer stability; in addition, it is not easily affected by sample autofluorescence. 11, 12 Moreover, multiple labeling analyses can be performed as the detection windows and wavelengths of lanthanide elements vary. Eu 3+ and Sm 3+ , which are used extensively in clinical and scientific research, use the same enhancer system containing β-naphthoyl trifluoroacetone (β-NTA) and a pair of common labels.
| D ISCUSS I ON
13,14
The Eu 3+ and Sm 3+ dual-labeled HCV-IgM/IgG TRFIA method established in this study can be used to simultaneously detect 
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